

TRIPLE AGONIST · GLP-1 / GIP
/ GCG

RETA.

One pen. Three receptors. Thirty milligrams.
A pre-filled Retatrutide pen at 30 mg per 3
ml, delivered as a single weekly
subcutaneous injection with 0.1 mg click
precision.

GLP-1

GIP

GLUCAGON



Three receptors. One weekly injection.

Retatrutide (LY-3437943) is a single molecule that agonises three metabolic receptors at once. In the Phase 2 obesity trial (Jastreboff et al., *NEJM* 2023), participants at 12 mg weekly achieved a mean **-24.2% body-weight reduction at 48 weeks** — the largest recorded loss of any incretin therapy to date.

GLP-1

01

Glucagon-like peptide-1 agonism slows gastric emptying, enhances glucose-dependent insulin release and suppresses appetite via the arcuate nucleus. This is the same axis targeted by semaglutide and tirzepatide.

GIP

02

Glucose-dependent insulinotropic polypeptide agonism improves insulin sensitivity and appears to modulate adipose tissue metabolism, contributing to fat-mass reduction beyond appetite suppression alone.

GCG-R

03

Glucagon-receptor agonism raises resting energy expenditure and drives hepatic lipid oxidation. This third arm is what distinguishes retatrutide from dual agonists and is credited with the larger fat-loss delta.

One injection weekly. Titrate by 1 mg every 4 weeks.

Subcutaneous injection into the abdomen, thigh or upper arm, once per week on a fixed day. Start low and step up by **1 mg every four weeks** to let GI tolerance build. The Phase 2 trial titrated to 12 mg over 24 weeks; the schedule below extends that ladder one milligram at a time so the transition between doses is gentler. Each 30 mg / 3 ml pen delivers 0.1 mg per click.

PHASE 01 1 mg WEEKS 1 - 4 10 CLICKS · WEEKLY	PHASE 02 2 mg WEEKS 5 - 8 20 CLICKS · WEEKLY	PHASE 03 3 mg WEEKS 9 - 12 30 CLICKS · WEEKLY	PHASE 04 4 mg WEEKS 13 - 16 40 CLICKS · WEEKLY	PHASE 05 5 mg WEEKS 17 - 20 50 CLICKS · WEEKLY	PHASE 06 6 mg WEEKS 21 - 24 60 CLICKS · WEEKLY
PHASE 07 7 mg WEEKS 25 - 28 70 CLICKS · WEEKLY	PHASE 08 8 mg WEEKS 29 - 32 80 CLICKS · WEEKLY	PHASE 09 9 mg WEEKS 33 - 36 90 CLICKS · WEEKLY	PHASE 10 10 mg WEEKS 37 - 40 100 CLICKS · WEEKLY	PHASE 11 11 mg WEEKS 41 - 44 110 CLICKS · WEEKLY	CEILING 12 mg WEEKS 45 - 48 120 CLICKS · WEEKLY

FULL PROTOCOL

48 weeks · 12 mg ceiling

Total exposure of 156 mg across the ladder. Do not exceed 12 mg weekly — this is the highest dose evaluated in the Phase 2 obesity trial and the ceiling used in the ongoing TRIUMPH Phase 3 programme. Hold or step back one phase if GI symptoms are limiting.

PEN MECHANICS

0.1 mg · per click

Dial the target dose in clicks (1 mg = 10 clicks). Inject subcutaneously, hold 10 seconds, withdraw and cap. One 30 mg pen covers the first four phases in full and part of phase 05.

Independently HPLC verified. Janoshik Analytical.

TASK #198194 · JUN 2026

Retatrutide

LY-3437943 · 30 MG / 3 ML

86.226%

M / M (MASS FRACTION)

99.364%

CHROMATOGRAPHIC PURITY

One molecule. Three metabolic levers.

Retatrutide is the first triple GLP-1 / GIP / glucagon agonist to reach Phase 3. Delivered here as a sealed 30 mg pen with 0.1 mg click precision and independent HPLC data — start at 1 mg, add 1 mg every four weeks, hold at the dose that works. Research use only.

AUTHENTICATE

www.zeuslabs.in/NFC